RAC media coverage, page-126

“They think the problem of the cardiotoxicity of doxorubicin has been “solved”. “
”The current ‘solution’ is to just limit the lifetime dosage to 240mg/m2. Sure this works to prevent damage to the hearts of most patients, but it is at the expense of being able to treat the cancer effectively. “

However, absolutely & of course :
“if you used an alternative chemotherapeutic without the cardiotoxicity you could then give far more treatment to the patient.” !!
As was also done and known to be the advantage as well as what is possible with Bisantrene - compared to SoC Doxorubicin.

In a nutshell - Thankyou Dr T .